Lexeo Therapeutics, Inc..
LXEO.US | Manufacture of pharmaceuticals, medicinal chemical and botanical products
Lexeo Therapeutics, Inc. is a clinical-stage gene therapy company focused on developing treatments for genetic diseases. The company's pipeline includes programs targeting central nervous system (CNS) and cardiovascular diseases. Their primary focus is on developing adeno-associated virus (AAV)-base...Show More
Better Health for All
0
No evidence available to assess Lexeo Therapeutics, Inc. on Better Health for All.
Fair Money & Economic Opportunity
0
Lexeo Therapeutics, Inc. is a clinical-stage gene therapy company focused on developing treatments for genetic diseases.
1
Its core business does not involve lending, insuring, moving, or storing money, nor does it offer financial services to consumers.
2
Therefore, all Key Performance Indicators (KPIs) related to 'Fair Money & Economic Opportunity,' which are designed to assess financial institutions, are not applicable to the company. No evidence was found in the provided articles to suggest the company engages in any activities that would fall under the scope of these financial KPIs.
3
Fair Pay & Worker Respect
0
No specific, quantitative data was found in the provided articles to assess Lexeo Therapeutics, Inc. against any of the Fair Pay & Worker Respect KPIs. Information regarding layoffs (15% of staff in April 2025, approximately 11 employees) was noted, but this does not directly map to voluntary turnover.
1
While some articles mentioned general benefits like health insurance or PTO for Lexeo Therapeutics, they did not provide the necessary quantitative percentages or ratios required by the rubric for any KPI, such as living wage coverage, CEO-to-median pay ratio, collective bargaining share, safety incident rate, pay equity ratio, worker engagement score, voluntary turnover rate, labor violation incidents, insecure contract share, or health insurance coverage.
2
,
3
A legal dispute regarding non-compete clauses was identified but does not constitute a labor-law violation against Lexeo's own employees.
4
Fair Trade & Ethical Sourcing
0
No specific, quantitative data points or concrete actions related to fair trade and ethical sourcing for LXEO.US's supply chain were found in the provided articles. Information regarding fair trade certifications, supplier audit frequency, incidents of forced or child labor, supply chain traceability, remediation speed for supplier violations, ethical clauses in supplier contracts, spend on high-risk materials, or supplier diversity spend is not available.
1
Article 6 explicitly states that sustainability data is not available for LXEO.
2
Honest & Fair Business
0
The company's audit committee develops procedures for employees to submit concerns anonymously about questionable accounting or audit matters.
1
An 'Open Door Policy for Reporting Complaints Regarding Accounting and Auditing Matters' exists, offering anonymous reporting via a toll-free telephone number and a dedicated email for the Compliance Officer.
2
Seven out of eight directors (87.5%) are considered independent under Nasdaq rules.
3
The company has a Code of Business Conduct and Ethics and a separate Anti-Corruption Policy, which applies to all employees, officers, and directors.
4
Gifts and entertainment are limited to U.S. $250.00 unless express permission is received.
5
KPMG LLP serves as the independent registered public accounting firm, auditing the company's financial statements for fiscal years 2023 and 2024.
6
The audit committee obtains and reviews an annual report from KPMG LLP describing internal quality control procedures and material issues.
7
Kind to Animals
0
No relevant evidence was found in the provided articles to assess Lexeo Therapeutics, Inc. against the 'Kind to Animals' ethical value.
No War, No Weapons
0
No specific, concrete data points were found in the provided articles for any of the KPIs related to the 'No War, No Weapons' value. The company's core business is clinical-stage gene therapy, and the articles primarily discuss financial reports, an expanded access policy, and a code of business conduct and ethics. These documents do not contain information regarding arms contracts, dual-use technology, sales to embargoed regimes, peacebuilding investments, or any other defense-related activities or policies. While the Code of Business Conduct and Ethics mentions compliance with U.S. Export Controls and Embargoes, this is a general policy statement and not specific evidence of actual sales volume, R&D investment in military dual-use technology, or board oversight of defense-related business activities.
1
Planet-Friendly Business
0
Lexeo Therapeutics, Inc. does not provide specific, concrete data points for any of the Planet-Friendly Business KPIs in the provided articles. The available information primarily focuses on financial performance, clinical trials, and general legal compliance. While the company's Code of Business Conduct and Ethics states an expectation for employees to comply with all applicable environmental laws, and its Nominating and Corporate Governance Committee reviews environmental, social responsibility, and sustainability matters, no quantitative data, specific programs, or outcomes related to emissions, renewable energy, water use, waste, certifications, or climate-related disclosures are present.
1
Respect for Cultures & Communities
0
The provided articles, including an IPO registration statement, clinical trial data, an expanded access policy, and patient materials, do not contain any specific, concrete data points or information relevant to Lexeo Therapeutics' performance regarding Respect for Cultures & Communities.
1
Therefore, no KPIs can be scored based on the evidence provided.
Safe & Smart Tech
-30
Lexeo Therapeutics states it has a Privacy Policy explaining how it treats information, including medical information, and that it uses technical and organizational security measures to protect personal data.
1
The company explicitly mentions compliance with the California Consumer Privacy Act (CCPA), the European Union Data Protection Regulation (GDPR), and the Children's Online Privacy Protection Act (COPPA), indicating good regulatory compliance.
2
However, the company's Privacy Policy states that personal data will be retained "as may be required or permitted by applicable law," which does not specify a limited retention period, suggesting limited data minimization practices.
3
For user data control, while California residents can make verifiable consumer requests for data access or portability twice within a 12-month period, the company also states it collects various data types including web browser information, IP address, geolocation, and device IDs, and uses tracking technologies like Google Analytics and Facebook Pixel, without clear evidence of comprehensive user control over these specific data points or tracking.
4
The company's Code of Conduct outlines annual training sessions for personnel on its policies, but no specific data on effectiveness or completion rates is provided.
5
Zero Waste & Sustainable Products
0
No information regarding waste diversion rates, product recyclability, packaging sustainability, recycled content, single-use plastic reduction, take-back programs, circular design principles, waste reduction initiatives, hazardous waste management, product durability, repairability, waste audit frequency, zero waste certification, waste disposal violations, material efficiency, packaging-to-product ratio, waste reduction targets, supplier waste requirements, or customer waste education was found in the provided articles.
1